BioScale said this week that it has appointed Martin Latterich as chief scientific officer.
Latterich is also chief scientific officer and a board member of the non-profit Nicholas Conor Institute for Pediatric Cancer Research. He has also been a professor at the Proteogenomics Research Institute for Systems Medicine and has held senior management positions at several companies including Diversa and Illumina.
Integrated Diagnostics announced this week that it has named Norman Hardman president of its new InDi Imaging division (see story this issue).
Hardman is currently non-executive director of Chelsea Therapeutics. He was previously the president and CEO of biotech consulting firm Oxalis Partners. Before that he held senior management positions at companies including Amicus Therapeutics, Enzon Pharmaceuticals, Onyx Pharmaceuticals, and GeneMedicine.
InDi also appointed University of California, Los Angeles professor Michael Phelps to the division as an advisor. The inventor of PET imaging technology, Phelps is the chair of the UCLA Department of Molecular and Medical Pharmacology and director of the Crump Institute for Molecular Imaging.